Latest Health News

Delorean Corporation has released its audited 2025 Annual Report, revealing key adjustments from its preliminary results including lower revenue, increased tax expenses, and a significant reclassification of borrowings.

FirstWave Cloud Technology has locked in a $2.5 million loan facility to accelerate its AI growth strategy and repay existing debt, complementing a recent $2.85 million equity raise.

Linius Technologies has released its audited FY2025 financial statements, revealing non-cash accounting adjustments related to Convertible Notes that increased reported losses and liabilities compared to prior unaudited figures.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

Orthocell has appointed its first Canadian distributor for Remplir, its innovative nerve repair device, ahead of an official launch at a major surgical conference in Vancouver. The move marks a significant step in expanding the product’s international footprint.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

RAM Essential Services Property Fund (REP) reports a Q1 FY26 distribution in line with guidance and reaffirms its full-year yield target while progressing its strategic transition to a healthcare-focused REIT.

Mayne Pharma’s innovative oral contraceptive NEXTSTELLIS® has secured reimbursement under Australia’s Pharmaceutical Benefits Scheme, making it significantly more affordable and broadening contraceptive options nationwide.

HITIQ Ltd has raised $250,000 through a premium-priced placement and secured a $1.4 million RDTI loan facility to support its pivot towards consumer concussion management technology.

Australian Unity Limited has appointed Kelly Bayer Rosmarin as its next Group Managing Director and CEO, succeeding Rohan Mead after his 21-year tenure. Bayer Rosmarin’s leadership is expected to drive the company’s strategic transformation and growth in wellbeing services.

Uscom Limited’s shares have been suspended from trading on the ASX due to concerns over its financial health, following a critical auditor’s disclaimer. The suspension will remain until the company meets regulatory requirements.

Island Pharmaceuticals has submitted a detailed briefing to the FDA aiming to accelerate approval of its antiviral Galidesivir for Marburg virus under the Animal Rule, with feedback expected by November.